Table 1Response of metastatic breast cancer to single-agent systemic therapy

DrugResponse Rate
Capecitabine20% to 36%
Docetaxel18% to 68%
Doxorubicin25% to 40%
Gemcitabine14% to 37%
Paclitaxel17% to 54%
Vinorelbine25% to 47%
Tamoxifen21% to 41%
Aromatase inhibitors10% to 20%
Trastuzumab12% to 34%

From: Overview of Resistance to Systemic Therapy in Patients with Breast Cancer

Cover of Madame Curie Bioscience Database
Madame Curie Bioscience Database [Internet].
Austin (TX): Landes Bioscience; 2000-2013.
Copyright © 2000-2013, Landes Bioscience.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.